Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00087659 · ClinicalTrials.gov registry record · NA
A Prostate Cancer Study in Men Undergoing Androgen Deprivation Therapy
A NA study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- NA
- Development phase
NCT00087659 is a NA study that has completed, run by Novartis Pharmaceuticals.
The verdict
NCT00087659, a NA study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
This study is being conducted to compare the effect of an investigational drug versus placebo on bone loss in men with prostate cancer who are receiving Androgen Deprivation Therapy (ADT). The study drug or placebo will be administered every three months of four treatments in one year. In order to participate, male patients 18 years and older must be consecutive veterans from participating Veterans Administration Medical Centers.
Interventions
- DRUG zoledronic acid
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-12 |
| Est. Completion | 2007-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00087659
The ClinicalTrials.gov registry entry for NCT00087659 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which zoledronic acid is the first listed.
NCT00087659 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00087659 about?
NCT00087659 is a clinical study titled "A Prostate Cancer Study in Men Undergoing Androgen Deprivation Therapy". This study is being conducted to compare the effect of an investigational drug versus placebo on bone loss in men with prostate cancer who are receiving Androgen Deprivation Therapy (ADT). The study drug or placebo will be administered every three months of four treatments in one year. In order to ...
What is the current status of trial NCT00087659?
This trial is currently completed. It is a NA study. The study started on 2003-12. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00087659?
The interventions under investigation include: zoledronic acid (DRUG).
Who is sponsoring clinical trial NCT00087659?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.